| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/10428190400010775 |
| P698 | PubMed publication ID | 15621779 |
| P50 | author | Dean D. Metcalfe | Q90856971 |
| P2093 | author name string | Hans-Peter Horny | |
| Karl Sotlar | |||
| Luis Escribano | |||
| Peter Valent | |||
| Wolfgang R Sperr | |||
| Michel Arock | |||
| Matthias Mayerhofer | |||
| Cem Akin | |||
| Manuela Födinger | |||
| Robert Fritsche-Polanz | |||
| P2860 | cites work | Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis | Q22001442 |
| The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis | Q24676988 | ||
| One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes | Q24685763 | ||
| CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy | Q28184867 | ||
| Treatment of cutaneous mastocytosis | Q28192647 | ||
| Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy | Q32054092 | ||
| A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val | Q33146408 | ||
| Mastocytosis: mediator-related signs and symptoms | Q33147535 | ||
| Hematologic manifestations of systemic mast cell disease: A prospective study of laboratory and morphologic features and their relation to prognosis | Q33375266 | ||
| Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders | Q33393956 | ||
| Increased bone marrow mast cells in preleukemic syndromes, acute leukemia, and lymphoproliferative disorders | Q33487332 | ||
| Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998. | Q33755884 | ||
| Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder | Q33784323 | ||
| Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis | Q33948611 | ||
| Diagnostic criteria and classification of mastocytosis: a consensus proposal | Q33948617 | ||
| Treatment of systemic mast cell disorders | Q33979061 | ||
| Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. | Q34066643 | ||
| Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. | Q43622703 | ||
| Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). | Q43623319 | ||
| Bone marrow findings in systemic mastocytosis | Q43628628 | ||
| Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. | Q43745319 | ||
| Stem cell factor-induced bone marrow mast cell hyperplasia mimicking systemic mastocytosis (SM): histopathologic and morphologic evaluation with special reference to recently established SM-criteria | Q43987776 | ||
| A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib | Q44534510 | ||
| Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit | Q44539087 | ||
| Imatinib for systemic mast-cell disease | Q44558628 | ||
| Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine | Q44678922 | ||
| Slowly progressive systemic mastocytosis with high mast-cell burden and no evidence of a non-mast-cell hematologic disorder: an example of a smoldering case? | Q44802499 | ||
| Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. | Q52461216 | ||
| Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver. | Q53381584 | ||
| CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. | Q54701336 | ||
| Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val | Q57826804 | ||
| Spleen colony-forming cell as common precursor for tissue mast cells and granulocytes | Q59060090 | ||
| Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. | Q34133511 | ||
| Mast cell leukemia: report of a case and review of the literature | Q34165793 | ||
| Mast cell leukaemia: evidence for bone marrow origin of the pathological clone | Q34165830 | ||
| Variable expression of activation-linked surface antigens on human mast cells in health and disease | Q34211542 | ||
| Clinical and histopathological aspects of cutaneous mastocytosis | Q34264289 | ||
| Diagnosis of mastocytosis: value of cytochemistry and immunohistochemistry | Q34264295 | ||
| Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. | Q34264299 | ||
| Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders | Q34264305 | ||
| Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis | Q34264308 | ||
| Mast cells and mast cell neoplasia: a review | Q34304654 | ||
| Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. | Q34580164 | ||
| Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression | Q34580198 | ||
| Cutaneous mastocytosis -- clinical heterogeneity. | Q34580209 | ||
| Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells | Q34658607 | ||
| Mastocytosis: current concepts in diagnosis and treatment | Q35026318 | ||
| Tryptase a novel biochemical marker of acute myeloid leukemia | Q35076231 | ||
| Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria | Q35101794 | ||
| Diagnosis and treatment of systemic mastocytosis: state of the art. | Q35203889 | ||
| Clinical, genetic, and therapeutic insights into systemic mast cell disease | Q35608106 | ||
| Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. | Q35612339 | ||
| Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis | Q35828746 | ||
| Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. | Q35829710 | ||
| Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand | Q36070756 | ||
| Spleen findings in generalized mastocytosis. A clinicopathologic study | Q36263416 | ||
| Classification and diagnosis of mastocytosis: current status | Q36518951 | ||
| The liver, spleen, and lymph nodes in mastocytosis | Q36518988 | ||
| The growth and differentiation of mast cells | Q36928390 | ||
| Mast cell sarcoma of the larynx | Q37208432 | ||
| Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product | Q38315689 | ||
| Liver findings in generalized mastocytosis. A clinicopathologic study | Q38598696 | ||
| Significance of systemic mast cell disease with associated hematologic disorders | Q39715028 | ||
| The riddle of the mast cell: kit(CD117)-ligand as the missing link? | Q40388512 | ||
| Detection of novel CD antigens on the surface of human mast cells and basophils | Q40731114 | ||
| The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations | Q40748765 | ||
| Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. | Q40764561 | ||
| Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior | Q40987642 | ||
| Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. | Q42937195 | ||
| Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His | Q43441750 | ||
| Treatment of systemic mast-cell disease with cladribine | Q43527780 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 35-48 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Leukemia & Lymphoma | Q6534493 |
| P1476 | title | Mastocytosis: pathology, genetics, and current options for therapy | |
| P478 | volume | 46 |
| Q51498353 | A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. |
| Q36660483 | A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast cell leukemia after allogeneic hematopoietic stem cell transplantation |
| Q33863692 | A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients |
| Q37609846 | Adult mastocytosis: a review of the Santo António Hospital 's experience and an evaluation of World Health Organization criteria for the diagnosis of systemic disease |
| Q37892475 | Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis |
| Q35807869 | Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. |
| Q90383114 | Allogeneic Hematopoietic Stem Cell Transplantation in a Rare Case of Tonsillar Mast Cell Sarcoma |
| Q38081373 | Anesthetic considerations in pediatric mastocytosis: a review |
| Q38711198 | BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils |
| Q37450689 | Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis |
| Q21092209 | Case-control cohort study of patients' perceptions of disability in mastocytosis |
| Q36374991 | Characterization of various types of mast cells derived from model mice of familial gastrointestinal stromal tumors with KIT-Asp818Tyr mutation |
| Q36337918 | Chronic myeloproliferative disorders: a tyrosine kinase tale. |
| Q36857947 | Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy. |
| Q36182758 | Clonality and molecular pathogenesis of mastocytosis. |
| Q37173105 | Cutaneous mastocytosis: a review focusing on the pediatric population |
| Q53646273 | Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies. |
| Q38431102 | Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation |
| Q38025156 | Diagnosis, progression patterns and prognostication in mastocytosis |
| Q54566864 | Diffuse cutaneous mastocytosis masquerading as epidermolysis bullosa. |
| Q33851724 | Eosinophilia in mast cell disease |
| Q34896142 | Gastrointestinal manifestations of systemic mastocytosis |
| Q37095268 | Generation and characterization of novel canine malignant mast cell line CL1. |
| Q45977986 | Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation. |
| Q33159586 | Hypotension, Syncope, and Fever in Systemic Mastocytosis without Skin Infiltration and Rapid Response to Corticosteroid and Cyclosporin: A Case Report |
| Q55088789 | Indolent Systemic Mastocytosis Manifesting as Protracted Anaphylactic Shock. |
| Q50536936 | Indolent systemic mastocytosis treated with narrow-band UVB phototherapy: study of five cases. |
| Q26830207 | KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis |
| Q34774009 | KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation |
| Q39193013 | KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570. |
| Q55266073 | Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway. |
| Q36782426 | Mast cell transcriptional networks |
| Q36835143 | Mast cells and mastocytosis |
| Q38723163 | Mast cells and their activation in lung disease |
| Q38040121 | Mast cells, disease and gastrointestinal cancer: A comprehensive review of recent findings |
| Q42243338 | Mastocytosis in children and adults: clinical disease heterogeneity |
| Q36403080 | Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation |
| Q36210845 | Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder |
| Q46023168 | Mastocytosis: the great masquerader. |
| Q38582624 | Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease |
| Q24313261 | Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells |
| Q36573324 | Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors |
| Q24656557 | MicroRNA-221-222 regulate the cell cycle in mast cells |
| Q46620513 | Mixed-lineage eosinophil/basophil crisis in MDS: a rare form of progression |
| Q36583570 | Novel approaches in the treatment of systemic mastocytosis |
| Q35631552 | Osteoporosis and osteopathy markers in patients with mastocytosis |
| Q35092066 | Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis |
| Q37810130 | Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. |
| Q39244862 | Proteasome inhibition upregulates Bim and induces caspase-3-dependent apoptosis in human mast cells expressing the Kit D816V mutation |
| Q34635424 | Recent advances in the understanding of mastocytosis: the role of KIT mutations. |
| Q53313967 | Receptor Tyrosine Kinase Expression Profiles in Canine Cutaneous and Subcutaneous Mast Cell Tumors. |
| Q42422156 | Regulation of normal and neoplastic human mast cell development in mastocytosis. |
| Q38773595 | Severe chronic diarrhea and maculopapular rash: a case report |
| Q42703964 | Systemic Mastocytosis in Association with Small Lymphocytic Lymphoma |
| Q42081445 | Systemic Mastocytosis with Smoldering Multiple Myeloma: Report of a Case |
| Q83304407 | Systemic mastocytosis |
| Q33861113 | Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma |
| Q33168552 | Systemic mastocytosis with KIT V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcome |
| Q42010978 | Systemic mastocytosis with acute myelomonocytic leukemia: a case report |
| Q33418580 | Systemic mastocytosis: a rare case of increased liver stiffness |
| Q54234141 | The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. |
| Q28480417 | The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils |
| Q38057806 | Therapeutic targeting of c-KIT in cancer |
| Q52935802 | Urinary 11β-PGF2α and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders. |
| Q42352568 | Urticaria Pigmentosa Mimicking Multiple Lentigine-like Brownish Macules in a 22-Month-Old Boy. |
| Q36527862 | Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment. |
| Q83130673 | Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow |
Search more.